ProPhase Labs (NASDAQ:PRPH) Coverage Initiated by Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

ProPhase Labs Trading Down 9.8 %

Shares of PRPH stock opened at $0.44 on Tuesday. The stock has a market cap of $10.51 million, a P/E ratio of -0.35 and a beta of -0.37. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48. ProPhase Labs has a fifty-two week low of $0.22 and a fifty-two week high of $7.48. The business has a fifty day simple moving average of $0.52 and a 200-day simple moving average of $1.42.

Institutional Investors Weigh In On ProPhase Labs

A number of large investors have recently bought and sold shares of PRPH. HighTower Advisors LLC raised its holdings in shares of ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after acquiring an additional 27,673 shares during the last quarter. Sheets Smith Wealth Management purchased a new stake in ProPhase Labs during the 4th quarter worth about $158,000. Geode Capital Management LLC raised its position in shares of ProPhase Labs by 9.2% in the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in ProPhase Labs in the 4th quarter worth approximately $40,000. Finally, Renaissance Technologies LLC raised its holdings in ProPhase Labs by 33.2% in the 4th quarter. Renaissance Technologies LLC now owns 286,485 shares of the company’s stock valued at $217,000 after acquiring an additional 71,375 shares during the last quarter. Institutional investors and hedge funds own 9.45% of the company’s stock.

ProPhase Labs Company Profile

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.